Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
In Focus channel feed
‘Harder to find homes’: Latest wave of biotech layoffs could test the industry
3 years ago
People
A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it
3 years ago
R&D
Decades after breakthrough, scientists still puzzling over mRNA delivery
3 years ago
R&D
Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up
3 years ago
Pharma
Cell/Gene Tx
How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research
3 years ago
Pharma
A stem cell pioneer sent an experiment into space. Patients are the next frontier
3 years ago
People
Cell/Gene Tx
The conference is back. What about the industry? Taking the biotech pulse at #JPM23
3 years ago
Financing
As money pours into digital therapeutics, insurance coverage crawls
3 years ago
R&D
Covid-19 spurred a historic vaccine R&D effort. What does it mean for future pandemics?
3 years ago
R&D
Coronavirus
A biotech paused a gene therapy hatched by families. Now they want control
3 years ago
Cell/Gene Tx
Father starts lab after intellectual property issues stymie rare disease drug development
3 years ago
People
Pharma
Even as pandemic recedes, short-staffed trial sites leave cancer patients waiting
3 years ago
R&D
Pharma
China's DNA giant confronts skepticism in US expansion bid
3 years ago
China
Diagnostics
After years of failures, the hunt for a new type of Parkinson’s drug is on
3 years ago
R&D
Biotech's 'sugar high' led to a correction, but winter doldrums could make way for a turnaround story this fall
3 years ago
Financing
Biotech’s downturn fuels a billionaire’s niche investment industry
3 years ago
R&D
Those big billion-dollar PhIII studies? Martin Landray says they can be done for a tiny fraction of the cost
3 years ago
R&D
Why non-opioid pain drugs keep failing — and what's next for the field
3 years ago
R&D
An MIT professor's rare disease quest ripples throughout biotech
3 years ago
People
After Roe, startups seek to fill Big Pharma’s male contraception gap
3 years ago
Startups
After abortion ruling, biotechs behind novel contraceptives say tide is turning on insurance coverage
3 years ago
DNA sequencing giant Illumina battles antitrust regulators and growing competition
3 years ago
Pharma
How prepared is biopharma for the cyber doomsday?
4 years ago
Pharma
A new era of treatment: How biomarkers are changing the way we think about cancer
4 years ago
R&D
First page
Previous page
2
3
4
5
6
7
8
Next page
Last page